Table 2.

Effects of cyclothiazide (100 μm) on the properties of evoked synaptic currents at −40 and +40 mV

ControlCyclothiazide
−40 mV+40 mV−40 mV+40 mV
EPSC amplitude (pA)−82.4  ± 16.8*,2-16423.1  ± 2.3−122.2  ± 15.922.0  ± 3.2
10–90% rise time (μsec)186.2  ± 11.6165.0  ± 23.6239.0  ± 17.5227.6  ± 17.0
τ1 (msec)0.91  ± 0.18*0.83  ± 0.11*1.95  ± 0.172.71  ± 0.44
τ2 (msec)3.25  ± 0.732-1602.86  ± 0.292-1609.34  ± 0.8418.74  ± 1.72
a1/(a1 + a2) (%)87.7  ± 8.091.7  ± 2.591.9  ± 2.375.8  ± 5.7
Weighted τ0.97  ± 0.16*1.0  ± 0.13*2.58  ± 0.356.57  ± 1.35
Charge transferred−99.7  ± 11.92-16038.3  ± 11.92-160−531.9  ± 77.7208.6  ± 34.9
Ampl (+40 mV/−40 mV)0.38  ± 0.150.18  ± 0.02
Ch T (+40 mV/−40 mV)0.44  ± 0.120.40  ± 0.04
  • Significant difference between EPSC properties at the same potential in control conditions and in the presence of cyclothiazide:

  • * p <0.05,

  • F2-160 p <0.005 and between EPSC properties at −40 and +40 mV in the same condition:

  • p <0.02,

  • F2-164 p < 0.005 by a two-tailed paired t test. n = 5.

  • Ampl (+40 mV/−40 mV), Ratio of EPSC amplitude at +40 versus −40 mV; Ch T (+40 mV/−40 mV), ratio of charge transfer of EPSC at +40 versus −40 mV. τ1 and τ2 are the time constants of decay of the fast and slow components of the EPSC; a1and a2 are their relative amplitudes.